MP-513

DRUG2 trials

Sponsors

Tanabe Pharma Corporation, Handok Inc.

Conditions

Type 2 Diabetes Mellitus

Phase 3

Pharmacokinetic/Pharmacodynamic Study of MP-513 With Type 2 Diabetes Mellitus

CompletedNCT01072331

Tanabe Pharma CorporationType 2 Diabetes Mellitus

Start: 2010-02-28End: 2010-08-31Updated: 2026-01-02

Teneligliptin(MP-513) Versus Placebo in Type 2 Diabetes Mellitus

CompletedNCT01798238

Handok Inc.Type 2 Diabetes Mellitus

Start: 2012-11-30End: 2014-05-31Updated: 2014-08-05